A third patient has died this year after getting a gene therapy from Sarepta Therapeutics Inc., raising questions about the ...

According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...

The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...

While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of Sarepta's investigational treatments.

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...

The Purdy family shares their insights on navigating their child’s rare neurodegenerative disease and their direct ...

Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST] ...